142 related articles for article (PubMed ID: 9085405)
21. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points.
Javanmard M; Shlik J; Kennedy SH; Vaccarino FJ; Houle S; Bradwejn J
Biol Psychiatry; 1999 Apr; 45(7):872-82. PubMed ID: 10202575
[TBL] [Abstract][Full Text] [Related]
22. Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers.
Maron E; Tõru I; Tasa G; Must A; Toover E; Lang A; Vasar V; Shlik J
Neurosci Lett; 2008 Dec; 446(2-3):88-92. PubMed ID: 18832011
[TBL] [Abstract][Full Text] [Related]
23. Neurobiological investigations into the role of cholecystokinin in panic disorder.
Bradwejn J
J Psychiatry Neurosci; 1993 Jul; 18(4):178-88. PubMed ID: 8104032
[TBL] [Abstract][Full Text] [Related]
24. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
25. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
26. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
27. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
28. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
29. CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects.
Maron E; Tõru I; Mäemets K; Sepp S; Vasar V; Shlik J; Zharkovsky A
J Psychopharmacol; 2009 Jun; 23(4):460-4. PubMed ID: 18562429
[TBL] [Abstract][Full Text] [Related]
30. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
[TBL] [Abstract][Full Text] [Related]
31. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
Koszycki D; Cox BJ; Bradwejn J
Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648
[TBL] [Abstract][Full Text] [Related]
32. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
33. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.
Ströhle A; Kellner M; Holsboer F; Wiedemann K
Am J Psychiatry; 2001 Sep; 158(9):1514-6. PubMed ID: 11532742
[TBL] [Abstract][Full Text] [Related]
34. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
35. The role of the 'central' cholecystokinin-B receptor in panic disorder.
Megen HJ; Westenberg HG; Boer JA
Acta Neuropsychiatr; 1996 Dec; 8(4):99-101. PubMed ID: 26964658
[TBL] [Abstract][Full Text] [Related]
36. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
37. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers.
Eser D; Leicht G; Lutz J; Wenninger S; Kirsch V; Schüle C; Karch S; Baghai T; Pogarell O; Born C; Rupprecht R; Mulert C
Hum Brain Mapp; 2009 Feb; 30(2):511-22. PubMed ID: 18095276
[TBL] [Abstract][Full Text] [Related]
38. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.
Sandmann J; Lörch B; Bandelow B; Härtter S; Winter P; Hiemke C; Benkert O
Pharmacopsychiatry; 1998 Jul; 31(4):117-21. PubMed ID: 9754844
[TBL] [Abstract][Full Text] [Related]
39. Effect of aging on cholecystokinin-induced panic.
Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
[TBL] [Abstract][Full Text] [Related]
40. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
Koszycki D; Torres S; Swain JE; Bradwejn J
Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
